- Home
- H vs BBIO Comparison
H vs BBIO Comparison
Compare H & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | H | BBIO |
|---|---|---|
| Founded | 1957 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 15.3B |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | H | BBIO |
|---|---|---|
| Price | $143.75 | $73.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $174.40 | $85.43 |
| AVG Volume (30 Days) | 670.7K | ★ 1.7M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,685,000,000.00 | $502,076,000.00 |
| Revenue This Year | $109.85 | $88.16 |
| Revenue Next Year | $6.64 | $74.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.78 | ★ 126.26 |
| 52 Week Low | $102.43 | $28.33 |
| 52 Week High | $180.53 | $84.94 |
Technical Indicators
Market Signals| Indicator | H | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 54.88 |
| Support Level | $136.17 | $69.62 |
| Resistance Level | $149.96 | $78.20 |
| Average True Range (ATR) | 4.59 | 2.64 |
| MACD | 0.39 | 0.58 |
| Stochastic Oscillator | 47.06 | 67.00 |
Price Performance
Historical ComparisonAbout H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 40 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.